ApconiX Welcomes Dr Bjorn Dahl

Bjorn Dahl

ApconiX is delighted to welcome Dr Björn Dahl to the team, who joins our new Swedish office at AstraZeneca’s BioVentureHub in Gothenburg.

Björn is a highly respected and experienced toxicologist, having been the co-chair of the European Federation Pharmaceutical Industry Association (EFPIA) Preclinical Development Expert Working Group and served as the EFPIA topic lead in the International Conference on Harmonisation (ICH) Expert Working Group developing a new guideline on nonclinical safety testing in support of development of paediatric medicines. Björn is a European Registered Toxicologist (ERT), a member of the Swedish Society of Toxicology as well as the Swedish National Registration board for ERT.

Björn has a BSc in biology and chemistry and a PhD in Environmental Toxicology from Gothenburg University. Björn worked at Astra AB and AstraZeneca R&D for over 20 years in nonclinical safety and has had different management as well as portfolio leadership roles. Björn was a Toxicology Project Leader, before becoming the Therapeutic Area/Lead Toxicologist for the Cardiovascular, Renal and Metabolism (CVRM) research division. In that role, he was a member of nonclinical safety as well as CVRM portfolio governance teams.

“I am looking forward to use the experience gained from 23 years of supporting projects in early and late stage development to help biotech and pharma companies bring effective, safe drugs to market quickly,” added Björn.

Dr Richard Knight, Director and Co-Founder of ApconiX, commented “We are very excited that Björn is joining ApconiX at our Gothenburg office. Having worked with him for many years, I know he’s is one of the most capable toxicologists around, and he brings a wealth of experience in early and late stage development. His knowledge, pragmatic approach and network will further enhance our ability to provide clients with the best advice for their projects.”